Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Matrixx’s Zicam Sales Up, Ad Spend Burns Profits In Tough Cough/Cold Market

This article was originally published in The Tan Sheet

Executive Summary

First-quarter profits for Matrixx Initiatives were dragged down in part by increased ad spending in the face of a "sharp decline" in sales for the overall cough/cold category, Executive VP and CFO William Hemelt stated in an earnings call April 25
Advertisement

Related Content

Most OTC Cough Meds Dismissed By Chest Physicians Guidelines
Most OTC Cough Meds Dismissed By Chest Physicians Guidelines

Topics

Advertisement
UsernamePublicRestriction

Register

PS099330

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel